Genetic Decryption of Leber Congenital Amaurosis (LCA) in a Large Cohort of Independent Families. (GENPHENACL)

November 18, 2016 updated by: Assistance Publique - Hôpitaux de Paris

Genetic Decryption of Leber Congenital Amaurosis (LCA) in a Large Cohort of Independent Families: Establishment of Genotype-phenotype Correlations and Updating the Clinical Definition of This Retinal Dystrophy

The main objectives of this study are:

  1. Improve genetic counseling by establishment of prevalences of each of genetic subtypes within a expanded population of patients with LCA taking into account ethnicity of families.
  2. Confirm, refine or modify the genotype-phenotype correlations.
  3. Edit important recommendations for:

    • The clinical and paraclinical exploration of a new patient based on genotype, especially for extraocular explorations, to book at certain genetic subtypes
    • Prenatal care of a couple.
    • Directing families to a therapeutic protocol in progress or in development.
  4. Individualize a panel of families without a mutation in the known genes and identify new genes responsible.

Study Overview

Status

Completed

Detailed Description

This study characterize the clinical history of the disease (age and start mode of visual disturbances, rate and mode of progress of disease), careful assessment of retina function and finally, in search of the mutations responsible for this condition.

A full ophthalmic check-up, one at the inclusion and 24 months :

  1. - A genetic consultation taking account of family history and establishment of family tree with precision of geographical origin of birth of ascendants.
  2. - A thorough ophthalmologic examination by a referring medical ophthalmologist, including:

    2.1 - An interrogation on the development of the visual awakening since the birth and its possible disturbances.

    2.2 - The search for abnormal movements of the eyeballs, and difficulties with regard to different lighting.

    2.3 - Visual field evaluation Survey.

    2.4 - The study of color vision.

    2.5 - The search for a refractive disorder with the automatic refractometer.

    2.6 - Measurement of Visual acuity for near and distance.

    2.7 - Examination of the eyeball as a whole, examination of the anterior chamber of the eye by the slit lamp.

    2.8 - Taking pictures of the fundus of the eye after pupillary dilation.

    2.9 - An autofluorescence search using a Scanning Laser Ophthalmoscopy (SLO).

    2.10 - Optical Coherence Tomography (OCT) which used to assess the thickness of each of retinal layers.

    2.11 - Electrophysiological examination, Electroretinogram (ERG) that allows to record the functional value of the retina.

    These two latter examinations last on average 10 minutes after dilation of the pupil.

  3. - A blood sample of 10 milliliters to carry out genetic studies to identify the gene responsible for this condition and genetic counseling refined by taking account the results of this study.

Intermediate visit M12: only for patients younger than 6 years of age on inclusion.

Study Type

Observational

Enrollment (Actual)

659

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Paris, France, 75015
        • Necker-Enfants Malades Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with Leber Congenital Amaurosis (LCA) taking into account Ethnicity of families.

Description

Inclusion Criteria:

Patients:

  • Patients of all ages
  • Patients with symptoms the day of the first consultation allowing to ask the diagnosis of leber congenital amaurosis.
  • Are affiliated to a social health care.
  • Written informed consent must be given by patients or holders parental authority for minors.

patients and siblings:

  • Signed consent for molecular study by the participant or by holders parental authority for minors.
  • Are affiliated to a social health care.

Exclusion Criteria:

  • Patients whose exploration has laid differential diagnoses.
  • Patients refusing the visits provided for in Protocol.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Retrospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Improve genetic counseling by establishment of prevalences of each of genetic subtypes within a expanded population of patients with LCA.
Time Frame: 24 MONTHS
24 MONTHS

Secondary Outcome Measures

Outcome Measure
Time Frame
Measurement of visual acuity using the logarithmic scale for children under 5
Time Frame: 24 MONTHS
24 MONTHS
Measurement of visual acuity using Early Treatment Diabetic Retinopathy Study scale (ETDRS) for far vision
Time Frame: 24 MONTHS
24 MONTHS
The "Parinaud Scale" for near vision (After the age of 6)
Time Frame: 24 MONTHS
24 MONTHS
Visual field evaluation Survey
Time Frame: 24 MONTHS
24 MONTHS
Measurement of refraction by portable automatic refractometer.
Time Frame: 24 MONTHS
24 MONTHS
Screening for color vision abnormalities using "children's boards" of "Ishihara Test" from the age of 3-4.
Time Frame: 24 MONTHS
24 MONTHS
Screening for color vision abnormalities using "regular boards" as soon as learning to read figures from the age of five.
Time Frame: 24 MONTHS
24 MONTHS
Test the color vision deficiency using the " Farnsworth test" in adults and children after the age of 6.
Time Frame: 24 MONTHS
24 MONTHS
The visual field test using the Goldman dome in adults and children aged 6 to 7.
Time Frame: 24 MONTHS
24 MONTHS
Electrophysiological examination using Electroretinogram.
Time Frame: 24 MONTHS
24 MONTHS

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Josseline KAPLAN, MD, Necker-Enfants Malades Hospital, 75015 Paris. France

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2010

Primary Completion (Actual)

September 1, 2015

Study Completion (Actual)

November 1, 2016

Study Registration Dates

First Submitted

November 17, 2016

First Submitted That Met QC Criteria

November 18, 2016

First Posted (Estimate)

November 21, 2016

Study Record Updates

Last Update Posted (Estimate)

November 21, 2016

Last Update Submitted That Met QC Criteria

November 18, 2016

Last Verified

November 1, 2016

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Leber Congenital Amaurosis

3
Subscribe